Revisiting "older" antimicrobials in the era of multidrug resistance

Pharmacotherapy

Volumn 31, Issue 9, 2011, Pages 912-921

  Pogue, Jason M ^a,b   Marchaim, Dror ^a,b   Kaye, Donald ^c   Kaye, Keith S ^a,c  

^a DETROIT MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Acinetobacter; Bactrim; Colistin; Fosfomycin; Methicillin resistant Staphylococcus aureus; Minocycline; MRSA; Multidrug resistance; Pseudomonas; Trimethoprim sulfamethoxazole

Indexed keywords

BACTERIAL PROTEIN; CARBAPENEM; CEFTAROLINE; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; DORIPENEM; FOSFOMYCIN; FOSFOMYCIN CALCIUM; FOSFOMYCIN TROMETAMOL; LINEZOLID; MINOCYCLINE; POLYMYXIN; RIFAMPICIN; SULTAMICILLIN; TELAVANCIN; TIGECYCLINE; TRIMETHOPRIM; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL MEMBRANE; BACTERIAL PNEUMONIA; BLOODSTREAM INFECTION; BREAKTHROUGH BACTEREMIA; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CENTRAL NERVOUS SYSTEM INFECTION; CREATINE KINASE BLOOD LEVEL; CYSTITIS; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ENDOCARDITIS; ENTEROBACTERIACEAE; ESCHERICHIA COLI INFECTION; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; KLEBSIELLA PNEUMONIAE INFECTION; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE DAMAGE; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; OSTEOMYELITIS; PANCREATITIS; PARESTHESIA; PHOTOSENSITIVITY; PNEUMOCYSTOSIS; PNEUMONIA; PROTEIN SYNTHESIS INHIBITION; PSEUDOMONAS; PSEUDOMONAS PNEUMONIA; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; STEVENS JOHNSON SYNDROME; SURGICAL INFECTION; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA; VERTIGO; VOMITING;

ANTI-INFECTIVE AGENTS; DRUG COSTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 80052227440     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.9.912     Document Type: Review

References (62)

1. Infectious Diseases Society of America. The 10 x '20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50:1081-3.
2. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
3. Wyeth Pharmaceuticals Inc. Tigecycline evaluation and surveillance trial (T.E.S.T.). Available from http://testsurveillance.com. Accessed January 10, 2011.
4. Wyeth Pharmaceuticals Inc. Tygacil (tigecycline) package insert. Philadelphia, PA; 2010.
5. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary tale. J Antimicrob Chemother 2007;59:128-31.
6. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46:567-70. (Pubitemid 351263497)
7. Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007;27:980-7. (Pubitemid 46986684)
8. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline Pharmacotherapy 2007;27:1198-201.
9. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline and imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68:140-51.
10. U.S. Food and Drug Administration. FDA drug safety communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections (09-01-2010). Available from http://www.fda.gov/ Drugs/DrugSafety/ucm224370.htm. Accessed January 10, 2011.
11. Paterson DL, DePestel DD. Doripenem. Clin Infect Dis 2009:49:291-8.
12. Chen LF, Kaye D. Current use for old antibacterial agents: polymyxins, rifamycins and aminoglycosides. Infect Dis Clin North Am 2009;23:1053-75.
13. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41. (Pubitemid 40570245)
14. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies [online exclusive article]. Crit Care. Available from http://dx.doi.org/10.1186/cc3995.
15. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant gramnegative bacteria. Int J Antimicrob Agents 2005;25:11-25. (Pubitemid 40023341)
16. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
17. Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010;30:1279-91.
18. Schulin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwest Germany. J Antimicrob Chemother 2002:49:403-6.
19. Marchaim D, Chopra T, Pogue JM, et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 2011;55:593-9.
20. Valencia R, Arroyo LA, Conde M, et al. Nosocomial outbreak with pan-drug resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 2009;30:257-63.
21. Poudyal A, Howden BP, Bell JM, et al. In vitro pharmacodynamics of colistin against multi-drug resistant Klebsiella pneumoniae. J. Antimicrob Chemother 2008;62:1311-18.
22. Li J, Rayner ER, Nation RL, et al. Heteroresistance to colistin in multi-drug resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006;50:2946-50.
23. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010;65:1019-27.
24. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009;48:1724-8.
25. Lee J, Kaye KS, Marchaim D, et al. Incidence of and risk factors for colistin associated nephrotoxicity at the Detroit Medical Center. Presented at the 50th interscience conference on antimicrobial agents and chemotherapy, Boston, MA, September 12-15, 2010.
26. Plachouras D, Karavan M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009:53:3430-6.
27. Kaye KS, Kaye D. Polymyxins (polymyxin B and colistin). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 6th ed. Philadelphia: Elsevier Inc., 2005:435-6.
28. Markov N, Markantonis SL, Dimitri E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008;30: 143-51. (Pubitemid 351834728)
29. Triax Pharmaceuticals LLC. Minocin (minocycline) package insert. Cranford, NJ; 2009.
30. Ruhe JJ, Monson T, Bradshe RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case-series and review of the literature. Clin Infect Dis 2005:40:1429-34.
31. Lawlor MT, Sullivan MC, Levitz RE, Quintiliani R, Nightengale C. Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J Infect Dis 1990;161:812-14.
32. Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med 2010;25:343-8.
33. Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med 2003;29:2072-6.
34. Meyers B, Salvatore M. Tetracyclines and chloramphenicol. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 6th ed. Philadelphia: Elsevier Inc., 2005:356-65.
35. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008;46:584-93. (Pubitemid 351263501)
36. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia among patients treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-20.
37. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200. (Pubitemid 351269157)
38. Grim SA, Rapp RP, Martin CA, Evans ME. Trimethoprimsulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005;25:253-64. (Pubitemid 40223485)
39. Tamer MA, Bray JD. Trimethoprim-sulfamethoxazole treatment of multiantibiotic resistant staphylococcal meningitis and endocarditis. Clin Ped 1982;21:125-6. (Pubitemid 12152853)
40. Yeldandi V, Strodtman R, Lentino JR. In-vitro and in-vivo studies of trimethoprim-sulfamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother 1998;22:873-80.
41. Bengtsson E, Svanbom M, Tunevall G. Trimethoprimsulphamethoxazole treatment in staphylococcal endocarditis and gram-negative septicemia. Scand J Infect Dis 1974;6:177-82.
42. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992;117: 390-8.
43. Goldberg E, Paul M, Talker O, et al. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. J Antimicrob Chemother 2010;65:1179-83.
44. Strom BL, Schinnar R, Apter AJ, et al. Absence of crossreactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003;349:1628-35. (Pubitemid 37288569)
45. Trollfors B, Wahl M, Alestig K. Co-trimoxazole, creatinine, and renal function. J Infect 1980:2:221-6.
46. Kalowski S, Singh Nanra R, Mathew TH, Kincaid-Smith P. Deterioration in renal function associated with co-trimoxazole therapy. Lancet 1973;1:394-7.
47. Josephson MA, Chiu MY, Woodle ES, Thistlethwaite JR, Haas M. Drug-induced acute interstitial nephritis in renal allografts: histopathologic features and clinical course in six patients. Am J Kidney Dis 1999;34:540-8. (Pubitemid 29413628)
48. Zinner SH, Mayer KH. Sulfonamides and trimethoprim. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 6th ed. Philadelphia, PA: Elsevier Inc., 2005:440-51.
49. Liu C, Cosgrove SE, Daum RS, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52: e18-55.
50. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46:1069-77. (Pubitemid 351589875)
51. Zambon Switzerland Ltd. Monurol (fosfomycin tromethamine) package insert. St. Louis, MO; 2007.
52. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. Fosfomycin for the treatment of infections caused by gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs 2009;18:921-44.
53. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multi-drug resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43-50.
54. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 2010;35:240-3.
55. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009;34:111-20.
56. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamics characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009;34:506-15.
57. Falagas ME, Vouloumanou EK, Togias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a metaanalysis of randomized controlled trials. J Antimicrob Chemother 2010;65:1862-77.
58. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrobial Agents 2007;29:62-5.
59. Shrestha NK, Amuh DA, Goldman MP, Riebel WJ, Tomford JW. Treatment of a complicated vancomycin resistant enterococcal urinary tract infection with fosfomycin. Infect Dis Clin Pract 2000;9:368-71. (Pubitemid 32062341)
60. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010;6:184-6.
61. Apisarnthanarak A, Mundy LM. Use of high dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia. Clin Infect Dis 2010;51:1351-2.
62. Florent A, Chichmanian RM, Cua E, Pulcini C. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents 2011;37:82-3.